ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
Marco RacioppiLuca Di GianfrancescoMauro RagoneseGiuseppe PalermoEmilio SaccoPier Francesco BassiPublished in: BMC cancer (2018)
EudraCT2017-002585-43. 17 June 2017 (retrospectively registered).